Skip to main content

Articles

Page 2 of 34

  1. Pathogenic heterozygous mutations in the progranulin gene (GRN) are a key cause of frontotemporal dementia (FTD), leading to significantly reduced biofluid concentrations of the progranulin protein (PGRN). This h...

    Authors: Imogen J. Swift, Rosa Rademakers, NiCole Finch, Matt Baker, Roberta Ghidoni, Luisa Benussi, Giuliano Binetti, Giacomina Rossi, Matthis Synofzik, Carlo Wilke, David Mengel, Caroline Graff, Leonel T. Takada, Raquel Sánchez-Valle, Anna Antonell, Daniela Galimberti…
    Citation: Alzheimer's Research & Therapy 2024 16:66
  2. It has been reported that the risk of Alzheimer’s disease (AD) could be predicted by the Australian National University Alzheimer Disease Risk Index (ANU-ADRI) scores. However, among non-demented Chinese adult...

    Authors: Shan Yin, Pei-Yang Gao, Ya-Nan Ou, Yan Fu, Ying Liu, Zuo-Teng Wang, Bao-Lin Han and Lan Tan
    Citation: Alzheimer's Research & Therapy 2024 16:65
  3. Posterior cortical atrophy (PCA) is a form of dementia that frequently displays significant visual dysfunction and relatively preserved cognitive and executive functions, thus hindering early diagnosis and tre...

    Authors: Yan Sun, Lumi Zhang, Hui Ye, Lumin Leng, Yi Chen, Yujie Su, Peifang Ren, Hong Lu and Guoping Peng
    Citation: Alzheimer's Research & Therapy 2024 16:64
  4. Alzheimer’s disease (AD) is the most common form of dementia, progressively impairing cognitive abilities. While neuroimaging studies have revealed functional abnormalities in AD, how these relate to aberrant ...

    Authors: Parul Verma, Kamalini Ranasinghe, Janani Prasad, Chang Cai, Xihe Xie, Hannah Lerner, Danielle Mizuiri, Bruce Miller, Katherine Rankin, Keith Vossel, Steven W. Cheung, Srikantan S. Nagarajan and Ashish Raj
    Citation: Alzheimer's Research & Therapy 2024 16:62
  5. Predicting future Alzheimer’s disease (AD)-related cognitive decline among individuals with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) is an important task for healthcare. Structural...

    Authors: Ida Arvidsson, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Nicholas Cullen, Shorena Janelidze, Pontus Tideman, Anders Heyden, Karl Åström, Oskar Hansson and Niklas Mattsson-Carlgren
    Citation: Alzheimer's Research & Therapy 2024 16:61
  6. Functional connectivity (FC) biomarkers play a crucial role in the early diagnosis and mechanistic study of Alzheimer’s disease (AD). However, the identification of effective FC biomarkers remains challenging....

    Authors: Ying Zhang, Le Xue, Shuoyan Zhang, Jiacheng Yang, Qi Zhang, Min Wang, Luyao Wang, Mingkai Zhang, Jiehui Jiang and Yunxia Li
    Citation: Alzheimer's Research & Therapy 2024 16:60
  7. We investigated whether the treatment needs of patients with dementia with Lewy bodies (DLB) and their caregivers, along with their attending physicians’ perception of those treatment needs, differ according t...

    Authors: Manabu Ikeda, Shunji Toya, Yuta Manabe, Hajime Yamakage and Mamoru Hashimoto
    Citation: Alzheimer's Research & Therapy 2024 16:59
  8. Cardiovascular health has been associated with dementia onset, but little is known about the variation of such association by sex and age considering dementia subtypes. We assessed the role of sex and age in t...

    Authors: Anna Ponjoan, Jordi Blanch, Ester Fages-Masmiquel, Ruth Martí-Lluch, Lia Alves-Cabratosa, María del Mar Garcia-Gil, Gina Domínguez-Armengol, Francesc Ribas-Aulinas, Lluís Zacarías-Pons and Rafel Ramos
    Citation: Alzheimer's Research & Therapy 2024 16:58
  9. In this study, the risk of dementia in patients with a history of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection was evaluated.

    Authors: Eunhae Shin, Sang Ah Chi, Tae-Young Chung, Hee Jin Kim, Kyunga Kim and Dong Hui Lim
    Citation: Alzheimer's Research & Therapy 2024 16:57
  10. Although abnormal accumulation of amyloid beta (Aβ) protein is thought to be the main cause of Alzheimer’s disease (AD), emerging evidence suggests a pivotal vascular contribution to AD. Aberrant amyloid β ind...

    Authors: Siqi Chen, Daji Guo, Yuanyuan Zhu, Songhua Xiao, Jiatian Xie, Zhan Zhang, Yu Hu, Jialin Huang, Xueying Ma, Zhiyuan Ning, Lin Cao, Jinping Cheng and Yamei Tang
    Citation: Alzheimer's Research & Therapy 2024 16:56
  11. Multimer detection system-oligomeric amyloid-β (MDS-OAβ) is a measure of plasma OAβ, which is associated with Alzheimer’s disease (AD) pathology. However, the relationship between MDS-OAβ and disease severity ...

    Authors: Sheng-Min Wang, Dong Woo Kang, Yoo Hyun Um, Sunghwan Kim, Chang Uk Lee, Philip Scheltens and Hyun Kook Lim
    Citation: Alzheimer's Research & Therapy 2024 16:55
  12. Due to the heterogeneity among patients with Mild Cognitive Impairment (MCI), it is critical to predict their risk of converting to Alzheimer’s disease (AD) early using routinely collected real-world data such...

    Authors: Qi Zhang, Ron Coury and Wenlong Tang
    Citation: Alzheimer's Research & Therapy 2024 16:54
  13. Studies have suggested that blood circulating phytosterols, plant-derived sterols analogous to cholesterol, were associated with blood lipid levels and the risk of Alzheimer’s disease (AD) and Parkinson’s dise...

    Authors: Xingzhi Guo, Jing Yu, Rui Wang, Ning Peng and Rui Li
    Citation: Alzheimer's Research & Therapy 2024 16:53
  14. The key to the prevention and treatment of Alzheimer’s disease (AD) is to be able to predict and diagnose AD at the preclinical or early stage, but the lack of a preclinical model of AD is the critical factor ...

    Authors: Xinxin Huang, Shanshan Huang, Fangyan Fu, Junzhen Song, Yuling Zhang and Feng Yue
    Citation: Alzheimer's Research & Therapy 2024 16:52
  15. LUMIPULSE G-automated immunoassays represent a widely used method for the quantification of Alzheimer’s disease (AD) biomarkers in the cerebrospinal fluid (CSF). Less invasive blood-based markers confer a prom...

    Authors: Anuschka Silva-Spínola, Maria João Leitão, Alicia Nadal, Nathalie Le Bastard, Isabel Santana and Inês Baldeiras
    Citation: Alzheimer's Research & Therapy 2024 16:51
  16. Growing evidence suggests that not only cerebrovascular disease but also Alzheimer’s disease (AD) pathological process itself cause cerebral white matter degeneration, resulting in white matter hyperintensitie...

    Authors: Woo-Jin Cha, Dahyun Yi, Hyejin Ahn, Min Soo Byun, Yoon Young Chang, Jung-Min Choi, Kyungtae Kim, Hyeji Choi, Gijung Jung, Koung Mi Kang, Chul-Ho Sohn, Yun-Sang Lee, Yu Kyeong Kim and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2024 16:50
  17. Primary progressive aphasia (PPA) diagnostic criteria underestimate the complex presentation of semantic (sv) and logopenic (lv) variants, in which symptoms partially overlap, and mixed clinical presentation (...

    Authors: Gaia Chiara Santi, Francesca Conca, Valentina Esposito, Cristina Polito, Silvia Paola Caminiti, Cecilia Boccalini, Carmen Morinelli, Valentina Berti, Salvatore Mazzeo, Valentina Bessi, Alessandra Marcone, Sandro Iannaccone, Se-Kang Kim, Sandro Sorbi, Daniela Perani, Stefano F. Cappa…
    Citation: Alzheimer's Research & Therapy 2024 16:49
  18. The clinical meaningfulness of the effects of recently approved disease-modifying treatments (DMT) in Alzheimer’s disease is under debate. Available evidence is limited to short-term effects on clinical rating...

    Authors: Linus Jönsson, Milana Ivkovic, Alireza Atri, Ron Handels, Anders Gustavsson, Julie Hviid Hahn-Pedersen, Teresa León, Mathias Lilja, Jens Gundgaard and Lars Lau Raket
    Citation: Alzheimer's Research & Therapy 2024 16:48
  19. Authors: Rong Jiang, Xue-Fei Wu, Bin Wang, Rong-Xiao Guan, Lang-Man Lv, Ai-Ping Li, Lei Lei, Ye Ma, Na Li, Qi-Fa Li, Quan-Hong Ma, Jie Zhao and Shao Li
    Citation: Alzheimer's Research & Therapy 2024 16:47

    The original article was published in Alzheimer's Research & Therapy 2020 12:47

  20. Polygenic effects have been proposed to account for some disease phenotypes; these effects are calculated as a polygenic risk score (PRS). This score is correlated with Alzheimer’s disease (AD)-related phenoty...

    Authors: Masataka Kikuchi, Akinori Miyashita, Norikazu Hara, Kensaku Kasuga, Yuko Saito, Shigeo Murayama, Akiyoshi Kakita, Hiroyasu Akatsu, Kouichi Ozaki, Shumpei Niida, Ryozo Kuwano, Takeshi Iwatsubo, Akihiro Nakaya and Takeshi Ikeuchi
    Citation: Alzheimer's Research & Therapy 2024 16:45
  21. GOIZ ZAINDU (“caring early” in Basque) is a pilot study to adapt the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) methodology to the Basque population and evalua...

    Authors: Mikel Tainta, Mirian Ecay-Torres, Maria de Arriba, Myriam Barandiaran, Ane Otaegui-Arrazola, Ane Iriondo, Maite Garcia-Sebastian, Ainara Estanga, Jon Saldias, Montserrat Clerigue, Alazne Gabilondo, Naia Ros, Justo Mugica, Aitziber Barandiaran, Francesca Mangialasche, Miia Kivipelto…
    Citation: Alzheimer's Research & Therapy 2024 16:44
  22. Glymphatic dysfunction is a crucial pathway for dementia. Alzheimer’s disease (AD) pathologies co-existing with cerebral small vessel disease (CSVD) is the most common pathogenesis for dementia. We hypothesize...

    Authors: Hui Hong, Luwei Hong, Xiao Luo, Qingze Zeng, Kaicheng Li, Shuyue Wang, Yeerfan Jiaerken, Ruiting Zhang, Xinfeng Yu, Yao Zhang, Cui Lei, Zhirong Liu, Yanxing Chen, Peiyu Huang and Minming Zhang
    Citation: Alzheimer's Research & Therapy 2024 16:43
  23. Optical coherence tomography angiography (OCT-A) is a novel tool that allows the detection of retinal vascular changes. We investigated the association of macular vessel density (VD) in the superficial plexus ...

    Authors: Ainhoa García-Sánchez, Oscar Sotolongo-Grau, Juan Pablo Tartari, Ángela Sanabria, Ester Esteban - De Antonio, Alba Pérez-Cordón, Montserrat Alegret, Vanesa Pytel, Joan Martínez, Núria Aguilera, Itziar de Rojas, Amanda Cano, Pablo García-González, Raquel Puerta, Clàudia Olivé, Maria Capdevila…
    Citation: Alzheimer's Research & Therapy 2024 16:42
  24. The relationship between periodontitis and Alzheimer’s disease (AD) has attracted more attention recently, whereas profiles of subgingival microbiomes and gingival crevicular fluid (GCF) metabolic signatures i...

    Authors: Che Qiu, Wei Zhou, Hui Shen, Jintao Wang, Ran Tang, Tao Wang, Xinyi Xie, Bo Hong, Rujing Ren, Gang Wang and Zhongchen Song
    Citation: Alzheimer's Research & Therapy 2024 16:41
  25. The use of structural and perfusion brain imaging in combination with behavioural information in the prediction of cognitive syndromes using a data-driven approach remains to be explored. Here, we thus examine...

    Authors: Ashwati Vipin, Bernett Teck Kwong Lee, Dilip Kumar, See Ann Soo, Yi Jin Leow, Smriti Ghildiyal, Faith Phemie Hui En Lee, Saima Hilal and Nagaendran Kandiah
    Citation: Alzheimer's Research & Therapy 2024 16:40
  26. Authors: Fernanda Schäfer Hackenhaar, Maria Josefsson, Annelie Nordin Adolfsson, Mattias Landfors, Karolina Kauppi, Magnus Hultdin, Rolf Adolfsson, Sofie Degerman and Sara Pudas
    Citation: Alzheimer's Research & Therapy 2024 16:39

    The original article was published in Alzheimer's Research & Therapy 2021 13:130

  27. Several studies have reported a relationship between retinal thickness and dementia. Therefore, optical coherence tomography (OCT) has been proposed as an early diagnosis method for Alzheimer’s disease (AD). I...

    Authors: María Eugenia Sáez, Ainhoa García-Sánchez, Itziar de Rojas, Emilio Alarcón-Martín, Joan Martínez, Amanda Cano, Pablo García-González, Raquel Puerta, Clàudia Olivé, Maria Capdevila, Fernando García-Gutiérrez, Miguel Castilla-Martí, Luis Castilla-Martí, Ana Espinosa, Montserrat Alegret, Mario Ricciardi…
    Citation: Alzheimer's Research & Therapy 2024 16:38
  28. CLARITY-AD is an 18-month, double-blinded, placebo-controlled, phase 3 trial which examined the safety and efficacy of the anti-amyloid agent, lecanemab, in mild cognitive impairment and mild dementia due to A...

    Authors: Rawan Tarawneh and Vernon S. Pankratz
    Citation: Alzheimer's Research & Therapy 2024 16:37
  29. Understanding the relationship among changes in Clinical Dementia Rating (CDR), patient outcomes, and probability of progression is crucial for evaluating the long-term benefits of disease-modifying treatments...

    Authors: Pierre N. Tariot, Mercè Boada, Krista L. Lanctôt, Julie Hahn-Pedersen, Firas Dabbous, Sariya Udayachalerm, Lars Lau Raket, Yuliya Halchenko, Wojciech Michalak, Wendy Weidner and Jeffrey Cummings
    Citation: Alzheimer's Research & Therapy 2024 16:36
  30. Sleep-wake regulating circuits are affected during prodromal stages in the pathological progression of both Alzheimer’s disease (AD) and Parkinson’s disease (PD), and this disturbance can be measured passively...

    Authors: Joseph R. Winer, Renske Lok, Lara Weed, Zihuai He, Kathleen L. Poston, Elizabeth C. Mormino and Jamie M. Zeitzer
    Citation: Alzheimer's Research & Therapy 2024 16:35
  31. Lack of early molecular biomarkers in sporadic behavioral variants of frontotemporal dementia (bvFTD) and its clinical overlap with primary psychiatric disorders (PPD) hampers its diagnostic distinction. Synap...

    Authors: Shreyasee Das, Marie-Paule E. van Engelen, Julie Goossens, Dirk Jacobs, Bram Bongers, Jay L. P. Fieldhouse, Yolande A. L. Pijnenburg, Charlotte E. Teunissen, Eugeen Vanmechelen and Inge M. W. Verberk
    Citation: Alzheimer's Research & Therapy 2024 16:34
  32. Authors: Lindsey I. Sinclair, Asher Mohr, Mizuki Morisaki, Martin Edmondson, Selina Chan, A. Bone‑Connaughton, Gustavo Turecki and Seth Love
    Citation: Alzheimer's Research & Therapy 2024 16:33

    The original article was published in Alzheimer's Research & Therapy 2023 15:153

  33. The blood-based biomarkers are approaching the clinical practice of Alzheimer’s disease (AD). Chronic kidney disease (CKD) has a potential confounding effect on peripheral protein levels. It is essential to ch...

    Authors: Jie Wu, Zhenxu Xiao, Mengjing Wang, Wanqing Wu, Xiaoxi Ma, Xiaoniu Liang, Li Zheng, Saineng Ding, Jianfeng Luo, Yang Cao, Zhen Hong, Jing Chen, Qianhua Zhao and Ding Ding
    Citation: Alzheimer's Research & Therapy 2024 16:32
  34. Limited data exist on the prevalence and trend of central nervous system (CNS)-active medication polypharmacy among adults with early-onset dementia (EOD) and whether these estimates differ for adults without ...

    Authors: Yu-Jung Jenny Wei, Nistha Shrestha, ChienWei Chiang and Steven T. DeKosky
    Citation: Alzheimer's Research & Therapy 2024 16:30
  35. Alzheimer’s disease (AD) is the sixth leading cause of death in the USA. It is established that neuroinflammation contributes to the synaptic loss, neuronal death, and symptomatic decline of AD patients. Accum...

    Authors: Kylene P. Daily, Asmaa Badr, Mostafa Eltobgy, Shady Estfanous, Owen Whitham, Michelle H. Tan, Cierra Carafice, Kathrin Krause, Andrew McNamara, Kaitlin Hamilton, Samuel Houle, Spandan Gupta, Gauruv A. Gupta, Shruthi Madhu, Julie Fitzgerald, Abbey A. Saadey…
    Citation: Alzheimer's Research & Therapy 2024 16:29
  36. Cardiometabolic multimorbidity is associated with an increased risk of dementia, but the pathogenic mechanisms linking them remain largely undefined. We aimed to assess the associations of cardiometabolic mult...

    Authors: Qiong-Yao Li, He-Ying Hu, Gao-Wen Zhang, Hao Hu, Ya-Nan Ou, Liang-Yu Huang, An-Yi Wang, Pei-Yang Gao, Li-Yun Ma, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2024 16:28
  37. Mild cognitive impairment (MCI) is a neurocognitive disorder in which the cognitive and mental abilities of humans are declined. Transcranial direct-current stimulation (tDCS) is an emerging noninvasive brain ...

    Authors: Soheila Rezakhani, Mahmood Amiri, Atefe Hassani, Khadijeh Esmaeilpour and Vahid Sheibani
    Citation: Alzheimer's Research & Therapy 2024 16:27
  38. Advancement in screening tools accessible to the general population for the early detection of Alzheimer’s disease (AD) and prediction of its progression is essential for achieving timely therapeutic intervent...

    Authors: Fernando García-Gutiérrez, Montserrat Alegret, Marta Marquié, Nathalia Muñoz, Gemma Ortega, Amanda Cano, Itziar De Rojas, Pablo García-González, Clàudia Olivé, Raquel Puerta, Ainhoa García-Sanchez, María Capdevila-Bayo, Laura Montrreal, Vanesa Pytel, Maitee Rosende-Roca, Carla Zaldua…
    Citation: Alzheimer's Research & Therapy 2024 16:26
  39. Secondary prevention clinical trials for Alzheimer’s disease (AD) target amyloid accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent other pathophysiological processes,...

    Authors: Clarissa D. Morales, Dejania Cotton-Samuel, Patrick J. Lao, Julia F. Chang, Jeffrey D. Pyne, Mohamad J. Alshikho, Rafael V. Lippert, Kelsang Bista, Christiane Hale, Natalie C. Edwards, Kay C. Igwe, Kacie Deters, Molly E. Zimmerman and Adam M. Brickman
    Citation: Alzheimer's Research & Therapy 2024 16:25
  40. Cholesterol is an essential component of the neuronal cell membrane and is crucial for neuronal function; however, the role of cholesterol levels in Parkinson’s disease (PD) is debatable. This study investigat...

    Authors: Seong Ho Jeong, Seok Jong Chung, Han Soo Yoo, Jin Ho Jung, Jong Sam Baik, Young H. Sohn and Phil Hyu Lee
    Citation: Alzheimer's Research & Therapy 2024 16:24
  41. Combining multimodal lifestyle interventions and disease-modifying drugs (novel or repurposed) could provide novel precision approaches to prevent cognitive impairment. Metformin is a promising candidate in vi...

    Authors: Mariagnese Barbera, Jenni Lehtisalo, Dinithi Perera, Malin Aspö, Mary Cross, Celeste A. De Jager Loots, Emanuela Falaschetti, Naomi Friel, José A. Luchsinger, Hanna Malmberg Gavelin, Markku Peltonen, Geraint Price, Anna Stigsdotter Neely, Charlotta Thunborg, Jaakko Tuomilehto, Francesca Mangialasche…
    Citation: Alzheimer's Research & Therapy 2024 16:23
  42. Alzheimer’s disease (AD) is one of the most burdening diseases of the century with no disease-modifying treatment at this time. Nonhuman primates (NHPs) share genetic, anatomical, and physiological similaritie...

    Authors: Zhouquan Jiang, Jing Wang, Yongpeng Qin, Shanggong Liu, Bin Luo, Fan Bai, Huiyi Wei, Shaojuan Zhang, Junjie Wei, Guoyu Ding, Long Ma, Shu He, Rongjie Chen, Ying Sun, Yi Chen, Lu Wang…
    Citation: Alzheimer's Research & Therapy 2024 16:22
  43. Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer’s disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such ...

    Authors: Veronika Matuskova, Katerina Veverova, Dylan J. Jester, Vaclav Matoska, Zahinoor Ismail, Katerina Sheardova, Hana Horakova, Jiri Cerman, Jan Laczó, Ross Andel, Jakub Hort and Martin Vyhnalek
    Citation: Alzheimer's Research & Therapy 2024 16:21
  44. Effective, disease-modifying therapeutics for the treatment of Alzheimer’s disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ ol...

    Authors: Christopher H. van Dyck, Adam P. Mecca, Ryan S. O’Dell, Hugh H. Bartlett, Nina G. Diepenbrock, Yiyun Huang, Mary E. Hamby, Michael Grundman, Susan M. Catalano, Anthony O. Caggiano and Richard E. Carson
    Citation: Alzheimer's Research & Therapy 2024 16:20
  45. Epileptic seizures are an established comorbidity of Alzheimer’s disease (AD). Subclinical epileptiform activity (SEA) as detected by 24-h electroencephalography (EEG) or magneto-encephalography (MEG) has been...

    Authors: Amber Nous, Laura Seynaeve, Odile Feys, Vincent Wens, Xavier De Tiège, Pieter Van Mierlo, Amir G. Baroumand, Koenraad Nieboer, Gert-Jan Allemeersch, Shana Mangelschots, Veronique Michiels, Julie van der Zee, Christine Van Broeckhoven, Annemie Ribbens, Ruben Houbrechts, Sara De Witte…
    Citation: Alzheimer's Research & Therapy 2024 16:19
  46. Authors: Francheska Delgado‑Peraza, Carlos Nogueras‑Ortiz, Anja Hviid Simonsen, De’Larrian DeAnté Knight, Pamela J. Yao, Edward J. Goetzl, Camilla Steen Jensen, Peter Høgh, Hanne Gottrup, Karsten Vestergaard, Steen Gregers Hasselbalch and Dimitrios Kapogiannis
    Citation: Alzheimer's Research & Therapy 2024 16:18

    The original article was published in Alzheimer's Research & Therapy 2023 15:156

  47. Plant-based diets may provide protection against cognitive decline and Alzheimer’s disease, but observational data have not been consistent. Previous studies include early life confounding from socioeconomic c...

    Authors: Claire T. McEvoy, Amy Jennings, Claire J. Steves, Alexander Macgregor, Tim Spector and Aedin Cassidy
    Citation: Alzheimer's Research & Therapy 2024 16:17